Therapeutic effects on white matter
Treatment strategies designed to target cancer cells are commonly associated with deleterious effects to multiple organ systems, including the central nervous system (CNS). As both radiation and chemotherapy alone can be associated with significant toxicity, the combination of radiation and chemotherapy may be, in particular, harmful to the CNS. With advanced treatment regimens and prolonged survival, neurological complications are likely to be observed with increasing frequency. Neurotoxicity can result from direct toxic effects of the treatment or radiation on the cells of the CNS, or indirectly through metabolic abnormalities, inflammatory processes, or vascular adverse effects.
Recognition of treatment-related neurologic complications is critically important, because symptoms may be confused with metastatic disease, tumor progression, paraneoplastic disorders, or opportunistic infections, and discontinuation of the offending drug may prevent irreversible CNS injury.
Radiation-associated neurotoxicity
It is widely accepted that the white matter of the central nervous system is prone to radiation-induced injury, compared with gray matter.
Radiation encephalopathy has been classically divided into three stages according to its timing after radiotherapy: early, early-delayed, and late-delayed reactions. Within the first several weeks of therapy, patients may experience acute declines in focal neurologic deficits. These effects are possibly related to increased edema, which has been supported by the observation that steroid treatment often results in clinical improvement. Early-delayed adverse effects, usually occur within 1-6 months of treatment, and are thought to be a result of demyelination. This syndrome is characterized by somnolence, fatigue, and cognitive dysfunction consistent with dysfunction of the frontal network systems. Late-delayed side effects occur months to years after cessation of treatment and are largely irreversible and progressive. These late changes are commonly associated with progressive cognitive deficits. In more severe cases of late-delayed radiation injury, imaging and histopathological studies may demonstrate leukoencephalopathy and/or focal necrosis.
Neuroimaging in radiation-induced neurotoxicity
In all types of white matter radiation-induced damage CT and mainly MRI may demonstrate variable degrees of white matter changes related to an increase in free tissue water in the involved areas. This may result from endothelial damage, causing increased capillary permeability and vasogenic edema, or from demyelination. However, the degree of these white matter changes correlates poorly with the functional deterioration observed in the patients.
MRI finding in early reactions occurring during course of treatment are nonspecific. MRI may be normal or demonstrate poorly defined multifocal lesions in both hemispheres that usually disappear spontaneously.
MRI in early-delayed reactions also may show signal changes involving not only the hemispheric white matter but also the basal ganglia and the cerebral peduncles, which resolve completely without treatment. These early-delayed changes have been reported in children with acute lymphatic leukemia who have been treated with both whole brain irradiation and chemotherapy (figure 1). These changes have no correlation with clinical manifestations and have no clear prognostic significance.
Late-delayed reactions can be subdivided into diffuse leukoencephalopathy and focal radiation-necrosis injury. The diffuse form is characterized by a progressive periventricular and subcortical leukoencephalopathy usually without contrast uptake (figure 2). These white matter changes are progressive and irreversible, and difficult to differentiate from signal changes secondary to normal aging or chronic vascular disease. These radiation-induced leukoencephalopathy may be associated with progressive brain atrophy, and patients may present with cognitive decline, gait abnormalities, and urinary incontinence.
However, the more common mild-to-moderate cognitive impairment is inconsistently associated with radiological findings, and frequently occurs in patients with normal-appearing MRI.
Recently, more sensitive tools to quantify the damage to brain tissue, such as diffusion tensor imaging (DTI) have been applied in patients treated with brain radiotherapy and have shown early and progressive diffuse changes in normal appearing white matter indicating radiation-induced demyelination and mild structural degradation of axonal fibers, which are indetectable with conventional MRI.
Mineralizing microangiopathy is a frequent neuroradiologic finding in children treated with radiation therapy, with or without concomitant chemotherapy (mainly methotrexate), caused by deposition of calcium within the small vessels of previously irradiated cerebral or cerebellar parenchyma.
Focal radiation-necrosis usually present as a ringlike or irregular enhancing mass lesion located in the white matter, which may become hemorrhagic.
The MRI features commonly seen in radiation necrosis are a soap bubble-like interior and Swiss cheese-like interior. Compared with lesions with the soap bubble pattern, Swiss cheese lesions are larger, more variable in size, and more diffuse. This pattern can be visualized as a result of diffuse necrosis affecting the white matter and cortex with diffuse enhancement at the margins with intermixed foci of necrosis.
The rim of enhancement is often thinner, more uniform, and more aligned to the gray-white junction than in malignant tumors. As radiation necrosis progresses, it can lead to severe shrinkage of the white matter and cortex and result in focal brain atrophy with hydrocephalus. When appear after radiation therapy of high-grade brain tumors, focal radiation-necrosis may be quite difficult to differentiate from tumor recurrence with conventional MRI.
The use of advanced MRI techniques, such as DWI, PWI and MRS, or PET scan can offer additional information that may substantially improve the ability to differentiate between the two entities.
Focal radiation-necrosis have been described in patients treated for residual pituitary tumours and nasopharyngeal or ethmoidal carcinoma. In nasopharyngeal carcinomas radiation induced focal necrosis typically involved uni or bilaterally the anterior temporal lobes (figure 3).
Chemotheraphy-associated neurotoxicity
Neurotoxicity has been observed with virtually all categories of chemotherapeutic agents. Neurologic complications may range from acute encephalopathy, headache, seizures, visual loss, cerebellar toxicity, and stroke to chronic side effects, including chronic encephalopathy, cognitive decline, and dementia Among the most puzzling aspects of cancer therapy-related toxicity is the occurrence of delayed and progressive neurological decline, even after cessation of treatment.
Anticancer agents affect brain function through both direct and indirect pathways. It is also conceivable that additional variables play important roles, including the timing of treatment, combination of different treatment modalities, patient age, integrity of the blood-brain barrier, and cognitive function prior to treatment initiation.
Neuroimaging in chemotherapy-induced neurotoxicity
Imaging studies have provided evidence that structural and functional CNS changes occur in a significant number of patients treated with chemotherapy. Some agents, such as methotrexate or carmustine, are well known to cause a leukoencephalopathy syndrome, especially when administered at a high dose, intrathecally, or in combination with cranial radiotherapy. Nonenhancing, confluent, periventricular white matter lesions, necrosis, ventriculomegaly, and cortical atrophy characterize this syndrome. White matter abnormalities following high-dose chemotherapy have been detected in up to 70% of treated individuals and usually have a delayed onset of several months.
A delayed leukoencephalopathy syndrome with distinct diffusion-weighted imaging abnormalities on MRI indicative of cytotoxic edema within cerebral white matter has been recently described. This syndrome appeared to mimic a stroke-like syndrome and has seen mainly in patients receiving methotrexate, 5-fluorouracil (5-FU), carmofur, and capecitabine (figure 4).
Posterior reversible leukoencephalopathy syndrome
Posterior reversible leukoencephalopathy syndrome (PRES) is a clinicoradiologic entity characterized by headaches, altered mental status, seizures, and visual loss, associated with predominantly posterior areas of vasogenic edema, as shown on neuroimaging studies. Although most cases of PRES occur in association with hypertension, many other medical conditions may also produce this syndrome, including the use of various drugs, such as immunosuppressive agents (cyclosporine A, tacrolimus, vincristine, cisplatin, or cytarabine among others). Toxic levels of a these drugs are not required for the development of PRES, and patients can become symptomatic after several months of exposure to a drug. Most patients, but not all, have some degree of hypertension, but blood pressure levels are usually lower than those typically encountered with pure hypertensive encephalopathy. PRES may be suspected on the basis of history, but the clinical signs and symptoms are nonspecific, and neuroradiological features are essential for establishing this diagnosis. At CT/MR imaging, the brain typically demonstrates reversible focal regions of symmetric hemispheric edema. The parietal and occipital lobes are most commonly affected, followed by the frontal lobes, the inferior temporal-occipital junction, and the cerebellum (figure 5). Focal/patchy areas of PRES vasogenic edema may also be seen in the basal ganglia, brain stem, and deep white matter (external/internal capsule). DWI consistently demonstrating that the areas of abnormality represent vasogenic edema.
Focal areas of restricted diffusion (likely representing infarction or tissue injury with cytotoxic edema) are uncommon and may be associated with an adverse outcome. Hemorrhage (focal hematoma, isolated sulcal/subarachnoid blood, or protein) is seen in approximately 15% of patients.
Conclusion
Standard oncological therapies, such as chemotherapy and cranial radiotherapy, frequently result in a spectrum of clinical and neurorradiological abnormalities. Early recognition of these treatment-related neurologic complications is critically important, in order to prevent or at least minimize irreversible CNS injury.
